Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.

Hallek, 2019, Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment, Am. J. Hematol., 94, 1266, 10.1002/ajh.25595 Herndon, 2017, Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood, Leuk., 31, 1340, 10.1038/leu.2017.11 Zent, 2011, FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes, Leuk Lymphoma, 52, 946, 10.3109/10428194.2011.565099 Herishanu, 2011, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia, Blood, 117, 563, 10.1182/blood-2010-05-284984 Swerdlow, 2017 Pugh, 1988, Paraimmunoblastic variant of small lymphocytic lymphoma/leukemia, Am J Surg Pathol, 12, 907, 10.1097/00000478-198812000-00002 Gine, 2010, Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior, Haematologica, 95, 1526, 10.3324/haematol.2010.022277 Boyd, 2013, Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results, Appl. Immunohistochem. Mol. Morphol., 21, 116, 10.1097/PAI.0b013e31825d550a Jain, 2012, Chronic lymphocytic leukemia with deletion 17p: emerging treatment options, Oncol. (Williston Park), 26, 1070 Matutes, 2000, Morphological and immunophenotypic features of chronic lymphocytic leukemia, Rev. Clin. Exp. Hematol., 4, 22, 10.1046/j.1468-0734.2000.00002.x Garces, 2018, Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption, Hum. Pathol., 82, 215, 10.1016/j.humpath.2018.07.030 Liu, 2020, Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis, Mod. Pathol., 33, 344, 10.1038/s41379-019-0356-z Ciccone, 2012, Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays, Leuk., 26, 499, 10.1038/leu.2011.247 Woyach, 2019, Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials, Blood, 134, 1796, 10.1182/blood.2019001321 Eichhorst, 2019, Relapsed disease and aspects of undetectable MRD and treatment discontinuation, Hematol. Am. Soc. Hematol. Educ. Prog., 2019, 482, 10.1182/hematology.2019000070 Tsang, 2015, The efficacy of ibrutinib in the treatment of richter syndrome, Blood, 125, 1676, 10.1182/blood-2014-12-610782 Fischer, 2018, Ibrutinib-induced rapid response in chemotherapy-refractory richter's syndrome, Hematol. Oncol., 36, 370, 10.1002/hon.2464 Allan, 2018, Current trends in the management of richter's syndrome, Int. J. Hematol. Oncol., 7, 10.2217/ijh-2018-0010 Khan, 2018, Approach to richter transformation of chronic lymphocytic leukemia in the era of novel therapies, Ann. Hematol., 97, 1, 10.1007/s00277-017-3149-9 Rossi, 2011, The genetics of richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, 117, 3391, 10.1182/blood-2010-09-302174 Maddocks, 2015, Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia, JAMA Oncol, 1, 80, 10.1001/jamaoncol.2014.218 Munir, 2019, Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, Am. J. Hematol., 94, 1353, 10.1002/ajh.25638 Burger, 2020, Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study, Leuk., 34, 787, 10.1038/s41375-019-0602-x Shanafelt, 2019, Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia, N. Engl. J. Med., 381, 432, 10.1056/NEJMoa1817073